iPhot receives a 940K€ grant

Article

iPhot, the collaborative project for continuing the development of Imagine Eyes' rtx1 Adaptive Optics Retinal Camera has received a 940K€ (approximately $US1.35M) grant from France's National Research Agency (ANR) TecSan programme.

iPhot, the collaborative project for continuing the development of Imagine Eyes' rtx1 Adaptive Optics Retinal Camera has received a 940K€ (approximately $US1.35M) grant from France's National Research Agency (ANR) TecSan programme.

“The ultimate goal of the iPhot project is to optimize the process of adaptive-optics enabled retinal imaging in order to obtain morphological, quantitative and longitudinal information at the level of single photoreceptor cells in humans” notes Imagine Eyes' CEO Nicolas Chateau. Adding: “Clinical investigations related to this particular project will be focused on early detection of photoreceptor damage in cases of genetically or phenotypically defined inheritable retinal dystrophies. As the project and its technology advances, we plan to partner with additional clinical investigation sites to perform research on the healthy retina as well as other retinal diseases.”

“Unfortunately, most cases retinal of disease are diagnosed only once the patient has suffered significant, irreparable vision loss” says Pr. Michel Paques, iPhot's Project Coordinator, from the Quinze-Vingts hospital. “Functional testing detects visual impairment only once a significant proportion of cells have degenerated. More importantly, functional defects, and the associated morphological changes at the level of outer segments, can precede cell loss. The current imaging technologies that are used to diagnose and monitor the effectiveness of treatment lack the cellular level resolution needed to observe the retinal microstructures causing the visual dysfunction. The comprehensive analysis of the relationship between structural and functional parameters will guide both prognostic assessment and therapeutic decision making in affected patients. It should equally provide clues to discriminate and quantify irreversible versus reversible lesions.”

To view images obtained with Imagine Eyes' adaptive-optics retinal camera, click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.